This roundtable series explores options regardless of past treatments in adult patients with polycythemia vera, as discussed by key opinion leaders at virtual live events and interviews.

Patients With Polycythemia Vera Eligible for Treatment Injection

Second-Line Considerations in Post-Hydroxyurea, High-Risk PV

July 09, 2026

During a live event, Kristen M. Pettit, MD, and participants discussed second-line considerations in high-risk polycythemia after hydroxyurea failure.

Emerging Evidence for Earlier Intervention in Low-Risk Polycythemia Vera

June 25, 2026

During a live event, Kristen M. Pettit, MD, discussed the potential of using treatment earlier in polycythemia vera to alter the disease course.

Considerations in the First-Line Setting in Polycythemia Vera

May 26, 2026

During a live event, Firas El Chaer, MD, highlighted pivotal data informing decision making in frontline polycythemia vera.

Optimizing Treatment Outcomes in Polycythemia Vera

April 22, 2026

The treatment landscape for high- and low-risk polycythemia vera is shifting with large scale studies such REVEAL and Low-PV changing practice.

Rampal Analyzes Ropeginterferon Data in Low-Risk Polycythemia Vera

September 16, 2025

During a live event, Raajit K. Rampal, MD, PhD, discussed ropeginterferon's potential to reduce JAK2 allele burden in low-risk polycythemia vera.

Treating Low-Risk Polycythemia Vera in the Second Line

August 28, 2025

During a live event, Raajit K. Rampal, MD, PhD, discusses managing a patient with low-risk polycythemia vera.

Studies Explore Control of Thrombotic Events in High-Risk PV

July 02, 2025

During a live event, Mojtaba Akhtari, MD, discussed trials studying patients with high-risk polycythemia vera.

Hematocrit Control, QOL Are Priorities in Low-Risk Polycythemia Vera

June 17, 2025

During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia vera.

Quality-of-Life Improvement Is Highly Valued in Polycythemia Vera

May 13, 2025

Douglas A. Tremblay, MD, discusses the importance of quality-of-life data from treating patients with polycythemia vera with ropeginterferon alfa-2b-njft.

Ropeginterferon Alfa Shows Disease-Modifying Potential in Polycythemia Vera

April 25, 2025

Douglas A. Tremblay, MD, discusses the data showing disease-modifying potential of ropeginterferon alfa-2b-njft in patients with polycythemia vera.

Ropeginterferon Alfa Reduces JAK2 Allele Burden Over Long Term in PV

March 28, 2025

Douglas A. Tremblay, MD, discusses the long-term data supporting ropeginterferon alfa-2b-njft as treatment in patients with polycythemia vera.

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Patients With Polycythemia Vera Eligible for Treatment Injection